{"commentary":{"count":24,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":13,"youtube":10,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03469674\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"PORTEC-4a","nct_id":"NCT03469674","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=portec-4a-nct03469674. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"PORTEC-4a","arms":[{"description":"Determination of the integrated clinicopathological and molecular profile to determine adjuvant treatment: observation for favourable profile; vaginal brachytherapy for intermediate profile; external beam radiotherapy for unfavourable profile","label":"Molecular profile based treatment","type":"EXPERIMENTAL"},{"description":"Adjuvant vaginal brachytherapy (standard treatment)","label":"Vaginal brachytherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Dutch Cancer Society","Comprehensive Cancer Centre The Netherlands"],"completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"conditions":["Endometrial Cancer Stage I","Endometrial Cancer Stage II"],"enrollment":{"count":550,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Vaginal brachytherapy","type":"RADIATION"},{"name":"External beam radiotherapy","type":"RADIATION"},{"name":"Observation","type":"OTHER"}],"last_update":"2023-10-11","lead_sponsor":"Leiden University Medical Center","official_title":"Randomised Phase III Trial of Molecular Profile-based Versus Standard Recommendations for Adjuvant Radiotherapy for Women With Early Stage Endometrial Cancer: PORTEC-4a Trial","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Vaginal recurrence","timeFrame":"5 years"}],"references":[{"citation":"van den Heerik ASVM, Horeweg N, Haverkort MAD, Kuijsters N, Kommoss S, Koppe FLA, Nowee ME, Westerveld H, De Jong MAA, Fruhauf F, Cnossen JS, Mens JWM, Beukema JC, Chargari C, Gillham C, Jurgenliemk-Schulz IM, Vandecasteele K, Hamann M, Kiderlen M, Staebler A, Nijman HW, Wortman BG, Asteinidou E, de Boer SM, van den Hout WB, Verhoeven-Adema KW, Nout RA, Putter H, Bosse T, Creutzberg CL. Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial. Lancet Oncol. 2026 Jan;27(1):23-35. doi: 10.1016/S1470-2045(25)00612-6.","pmid":"41449145","type":"DERIVED"},{"citation":"Nero C, Ciccarone F, Pietragalla A, Duranti S, Daniele G, Scambia G, Lorusso D. Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment. Front Oncol. 2021 Sep 1;11:612450. doi: 10.3389/fonc.2021.612450. eCollection 2021.","pmid":"34540651","type":"DERIVED"},{"citation":"van den Heerik ASVM, Horeweg N, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld GH, van den Berg HA, Slot A, Koppe FLA, Kommoss S, Mens JWM, Nowee ME, Bijmolt S, Cibula D, Stam TC, Jurgenliemk-Schulz IM, Snyers A, Hamann M, Zwanenburg AG, Coen VLMA, Vandecasteele K, Gillham C, Chargari C, Verhoeven-Adema KW, Putter H, van den Hout WB, Wortman BG, Nijman HW, Bosse T, Creutzberg CL. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer. 2020 Dec;30(12):2002-2007. doi: 10.1136/ijgc-2020-001929. Epub 2020 Oct 12.","pmid":"33046573","type":"DERIVED"},{"citation":"Wortman BG, Bosse T, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld H, van den Berg H, Slot A, De Winter KAJ, Verhoeven-Adema KW, Smit VTHBM, Creutzberg CL; PORTEC Study Group. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial. Gynecol Oncol. 2018 Oct;151(1):69-75. doi: 10.1016/j.ygyno.2018.07.020. Epub 2018 Aug 3.","pmid":"30078506","type":"DERIVED"}],"start_date":{"date":"2016-06-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer","url":"https://clinicaltrials.gov/study/NCT03469674"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/portec-4a-nct03469674"}